chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during breast feeding, Pruritus
Clinical narrative: dizzy; maternal exposure during breast feeding; headache; Bruising; redness; itchiness; warm to the touch; This spontaneous case was reported by a consumer and describes the occurrence of CONTUSION (Bruising), ERYTHEMA (redness), PRURITUS (itchiness), FEELING HOT (warm to the touch) and DIZZINESS (dizzy) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022B21A and 027B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-May-2021, the patient experienced CONTUSION (Bruising), ERYTHEMA (redness), PRURITUS (itchiness), FEELING HOT (warm to the touch), MATERNAL EXPOSURE DURING BREAST FEEDING (maternal exposure during breast feeding) and HEADACHE (headache). On 17-May-2021, the patient experienced DIZZINESS (dizzy). The patient was treated with IBUPROFEN at a dose of 1 dosage form. On 14-May-2021, MATERNAL EXPOSURE DURING BREAST FEEDING (maternal exposure during breast feeding) had resolved. At the time of the report, CONTUSION (Bruising), ERYTHEMA (redness), PRURITUS (itchiness), FEELING HOT (warm to the touch), DIZZINESS (dizzy) and HEADACHE (headache) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable.  No concomitant medications provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jun-2021: TCR received on 18-jun-2021 contains Consent declined to Follow-up.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Depression, Fatigue, Malaise
Clinical narrative: Depression symptoms coming up; Not thinking as well/ Not active/not able to get out of bed; Feeling tired; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DEPRESSION (Depression symptoms coming up), MALAISE (Not thinking as well/ Not active/not able to get out of bed) and FATIGUE (Feeling tired) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included BUPROPION HYDROCHLORIDE (WELLBUTRIN) and DULOXETINE HYDROCHLORIDE (CYMBALTA) for Depression, ARIPIPRAZOLE (ABILIFY) and QUETIAPINE FUMARATE (SEROQUEL) for Psychotic disorder.   On 27-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 03-May-2021, the patient experienced DEPRESSION (Depression symptoms coming up), MALAISE (Not thinking as well/ Not active/not able to get out of bed) and FATIGUE (Feeling tired). At the time of the report, DEPRESSION (Depression symptoms coming up), MALAISE (Not thinking as well/ Not active/not able to get out of bed) and FATIGUE (Feeling tired) outcome was unknown.            The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was not applicable. Treatment information was not provided. Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Joint swelling, Paraesthesia, Vaccination site pain, Vaccination site swelling
Clinical narrative: magnetic pull on left arm and then the magnetic pull moved to her forehead; tingling of left elbow; swelling and tingling of left elbow; pain and swelling at injection site of left arm; swelling at injection site of left arm; This spontaneous case was reported by a patient and describes the occurrence of PARAESTHESIA (tingling of left elbow), FEELING ABNORMAL (magnetic pull on left arm and then the magnetic pull moved to her forehead), VACCINATION SITE PAIN (pain and swelling at injection site of left arm), VACCINATION SITE SWELLING (swelling at injection site of left arm) and JOINT SWELLING (swelling and tingling of left elbow) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced VACCINATION SITE PAIN (pain and swelling at injection site of left arm) and VACCINATION SITE SWELLING (swelling at injection site of left arm). On 10-May-2021, the patient experienced PARAESTHESIA (tingling of left elbow) and JOINT SWELLING (swelling and tingling of left elbow). On 13-May-2021, the patient experienced FEELING ABNORMAL (magnetic pull on left arm and then the magnetic pull moved to her forehead). On 11-May-2021, PARAESTHESIA (tingling of left elbow) and JOINT SWELLING (swelling and tingling of left elbow) had resolved. On 15-May-2021, FEELING ABNORMAL (magnetic pull on left arm and then the magnetic pull moved to her forehead) had resolved. At the time of the report, VACCINATION SITE PAIN (pain and swelling at injection site of left arm) and VACCINATION SITE SWELLING (swelling at injection site of left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication information was not provided.  Treatment information was not provided.   This case was linked to MOD21-090969 (E2B Linked Report).; Sender's Comments:  MOD21-090969:
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Mobility decreased, Pain in extremity
Clinical narrative: Sore Right Arm (After First Vaccine); Could not move Right Arm (After First Vaccine); This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore Right Arm (After First Vaccine)) and MOBILITY DECREASED (Could not move Right Arm (After First Vaccine)) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, the patient experienced PAIN IN EXTREMITY (Sore Right Arm (After First Vaccine)) and MOBILITY DECREASED (Could not move Right Arm (After First Vaccine)). On 15-Apr-2021, PAIN IN EXTREMITY (Sore Right Arm (After First Vaccine)) and MOBILITY DECREASED (Could not move Right Arm (After First Vaccine)) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.   This case was linked to MOD-2021-138860 (Patient Link).
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Gingival discomfort, Gingival swelling, Pain, Pyrexia, Vaccination site pain
Clinical narrative: Irritable gums; Swollen gums; Generalized body pains; Pain at injection site; Mild Fever; This spontaneous case was reported by a consumer and describes the occurrence of GINGIVAL DISCOMFORT (Irritable gums), GINGIVAL SWELLING (Swollen gums), PAIN (Generalized body pains), VACCINATION SITE PAIN (Pain at injection site) and PYREXIA (Mild Fever) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025C21A and 043B21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension and Peptic ulcer. Concomitant products included AMLODIPINE for Hypertension, OMEPRAZOLE for Peptic ulcer, ACETYLSALICYLIC ACID (BABY ASPIRIN), VITAMIN B COMPLEX, FOLIC ACID and ASCORBIC ACID, VACCINIUM MACROCARPON (CRANBERRY [ASCORBIC ACID;VACCINIUM MACROCARPON]) for an unknown indication.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-May-2021, the patient experienced PAIN (Generalized body pains), VACCINATION SITE PAIN (Pain at injection site) and PYREXIA (Mild Fever). On 15-May-2021, the patient experienced GINGIVAL DISCOMFORT (Irritable gums) and GINGIVAL SWELLING (Swollen gums). At the time of the report, GINGIVAL DISCOMFORT (Irritable gums) and GINGIVAL SWELLING (Swollen gums) had not resolved and PAIN (Generalized body pains), VACCINATION SITE PAIN (Pain at injection site) and PYREXIA (Mild Fever) outcome was unknown.            Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 19-May-2021: Follow up received contains no significant information. Updated patient date of birth.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Antibody test, Body temperature, Pyrexia, Vaccination site pain
Clinical narrative: localized pain at injection site; fever; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (localized pain at injection site) and PYREXIA (fever) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K20A and 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (localized pain at injection site) and PYREXIA (fever). At the time of the report, VACCINATION SITE PAIN (localized pain at injection site) outcome was unknown and PYREXIA (fever) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2021, Body temperature: 98.5 (High) body temperature was recorded as 98.5 for around 15 hours. On 17-May-2021, Antibody test: negative (Negative) On 17-MAY-2021 results came that no antibodies are present.         No concomitant medications were reported.  No treatment details were reported.  Event outcome for injection site pain was not reported.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: Tested positive for Covid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for Covid) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-May-2021, the patient experienced COVID-19 (Tested positive for Covid). At the time of the report, COVID-19 (Tested positive for Covid) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       no concomitant medications are provided.
Sex: U
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Their arm was sore at the injection site.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Their arm was sore at the injection site.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Apr-2021, the patient experienced PAIN IN EXTREMITY (Their arm was sore at the injection site.). At the time of the report, PAIN IN EXTREMITY (Their arm was sore at the injection site.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment was reported.    This case was linked to INC.-MOD-2021-138343, INC.-MOD-2021-138859 (E2B Linked Report).; Sender's Comments: INC.-MOD-2021-138343:Case cross linked dose 1 for the 3 family members, INC.-MOD-2021-138859:Case cross linked dose 1 for the 3 family members.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Received vaccine from a vial that was exposed to room temperature for more than 12 hours; This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received vaccine from a vial that was exposed to room temperature for more than 12 hours) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received vaccine from a vial that was exposed to room temperature for more than 12 hours). On 14-May-2021, EXPIRED PRODUCT ADMINISTERED (Received vaccine from a vial that was exposed to room temperature for more than 12 hours) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. It was reported that the patient was fine and did not had any side effects. No treatment medications were reported.   This case was linked to MOD21-090714, US-MODERNATX, INC.-MOD-2021-138701, US-MODERNATX, INC.-MOD-2021-138817 (E2B Linked Report).; Sender's Comments:  MOD21-090714: US-MODERNATX, INC.-MOD-2021-138701: US-MODERNATX, INC.-MOD-2021-138817:
Age: 71.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: Dyspnoea exertional, Heart rate increased, Oxygen saturation decreased
Clinical narrative: heart rate increased; oxygen saturation decreased; dyspnoea exertional; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (heart rate increased), OXYGEN SATURATION DECREASED (oxygen saturation decreased) and DYSPNOEA EXERTIONAL (dyspnoea exertional) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TREPROSTINIL SODIUM (TYVASO) for Pulmonary arterial hypertension.    Concurrent medical conditions included Pulmonary arterial hypertension.   On 02-Apr-2021, the patient started TREPROSTINIL SODIUM (TYVASO) (unknown route) .6 mg four times per day. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-May-2021, the patient experienced HEART RATE INCREASED (heart rate increased), OXYGEN SATURATION DECREASED (oxygen saturation decreased) and DYSPNOEA EXERTIONAL (dyspnoea exertional). At the time of the report, HEART RATE INCREASED (heart rate increased), OXYGEN SATURATION DECREASED (oxygen saturation decreased) and DYSPNOEA EXERTIONAL (dyspnoea exertional) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator  No treatment medications provided by the reporter   Most recent FOLLOW-UP information incorporated above includes: On 13-Jun-2021: Follow-up received, email response included NNi
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Lymphadenopathy, Neck pain, Pain in extremity
Clinical narrative: In so much pain at the base of the neck; she has enlarged lymph nodes on the side of the injection; Pain in legs; swollen legs; Tired; Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine; Chills; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Pain in legs), PERIPHERAL SWELLING (swollen legs), NECK PAIN (In so much pain at the base of the neck), FATIGUE (Tired) and LYMPHADENOPATHY (Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038A21A and 014M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Cancer.   On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Apr-2021, the patient experienced PAIN IN EXTREMITY (Pain in legs), PERIPHERAL SWELLING (swollen legs), FATIGUE (Tired), LYMPHADENOPATHY (Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine) and CHILLS (Chills). On an unknown date, the patient experienced NECK PAIN (In so much pain at the base of the neck) and VACCINATION SITE LYMPHADENOPATHY (she has enlarged lymph nodes on the side of the injection). At the time of the report, PAIN IN EXTREMITY (Pain in legs), PERIPHERAL SWELLING (swollen legs), NECK PAIN (In so much pain at the base of the neck), FATIGUE (Tired), LYMPHADENOPATHY (Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine), CHILLS (Chills) and VACCINATION SITE LYMPHADENOPATHY (she has enlarged lymph nodes on the side of the injection) outcome was unknown.            Unspecified cancer medication was used by the patient as concomitant mediction. Patient was asked to take unspecified pain medication  as treatment drug. Health care provider stated that the side effects were due to the vaccine and was asked to take ultrasound and blood tests.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jun-2021: Significant Follow-up
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Vaccination site lymphadenopathy
Clinical narrative: In so much pain at the base of the neck; she has enlarged lymph nodes on the side of the injection; Pain in legs; swollen legs; Tired; Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine; Chills; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Pain in legs), PERIPHERAL SWELLING (swollen legs), NECK PAIN (In so much pain at the base of the neck), FATIGUE (Tired) and LYMPHADENOPATHY (Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038A21A and 014M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Cancer.   On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Apr-2021, the patient experienced PAIN IN EXTREMITY (Pain in legs), PERIPHERAL SWELLING (swollen legs), FATIGUE (Tired), LYMPHADENOPATHY (Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine) and CHILLS (Chills). On an unknown date, the patient experienced NECK PAIN (In so much pain at the base of the neck) and VACCINATION SITE LYMPHADENOPATHY (she has enlarged lymph nodes on the side of the injection). At the time of the report, PAIN IN EXTREMITY (Pain in legs), PERIPHERAL SWELLING (swollen legs), NECK PAIN (In so much pain at the base of the neck), FATIGUE (Tired), LYMPHADENOPATHY (Swollen lymph node/she has enlarged lymph nodes on the side of the injection, and is now having them on the other side. Consumer stated her health care providers have stated it is due to the vaccine), CHILLS (Chills) and VACCINATION SITE LYMPHADENOPATHY (she has enlarged lymph nodes on the side of the injection) outcome was unknown.            Unspecified cancer medication was used by the patient as concomitant mediction. Patient was asked to take unspecified pain medication  as treatment drug. Health care provider stated that the side effects were due to the vaccine and was asked to take ultrasound and blood tests.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jun-2021: Significant Follow-up
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Lip swelling, Neck mass, Product dose omission issue, Rash, Skin discolouration
Clinical narrative: denied them their second dose due to their reaction to the first dose; lump on her neck; White spots; Hives on her chest; Rash; lips swollen; Tongue swollen; Face swollen; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives on her chest ), RASH (Rash), LIP SWELLING (lips swollen), SWOLLEN TONGUE (Tongue swollen) and SWELLING FACE (Face swollen) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below.     Concomitant products included IBUPROFEN (ADVIL [IBUPROFEN]) and LORATADINE (CLARITIN [LORATADINE]) for an unknown indication.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced URTICARIA (Hives on her chest ), RASH (Rash), LIP SWELLING (lips swollen), SWOLLEN TONGUE (Tongue swollen) and SWELLING FACE (Face swollen). On 07-May-2021, the patient experienced SKIN DISCOLOURATION (White spots). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (denied them their second dose due to their reaction to the first dose) and NECK MASS (lump on her neck). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 2 doses. At the time of the report, URTICARIA (Hives on her chest ) and NECK MASS (lump on her neck) was resolving and RASH (Rash), LIP SWELLING (lips swollen), SWOLLEN TONGUE (Tongue swollen), SWELLING FACE (Face swollen), SKIN DISCOLOURATION (White spots) and PRODUCT DOSE OMISSION ISSUE (denied them their second dose due to their reaction to the first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to US-MODERNATX, INC.-MOD-2021-138803 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-138803:Mother's case
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling face, Swollen tongue, Urticaria
Clinical narrative: denied them their second dose due to their reaction to the first dose; lump on her neck; White spots; Hives on her chest; Rash; lips swollen; Tongue swollen; Face swollen; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives on her chest ), RASH (Rash), LIP SWELLING (lips swollen), SWOLLEN TONGUE (Tongue swollen) and SWELLING FACE (Face swollen) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below.     Concomitant products included IBUPROFEN (ADVIL [IBUPROFEN]) and LORATADINE (CLARITIN [LORATADINE]) for an unknown indication.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced URTICARIA (Hives on her chest ), RASH (Rash), LIP SWELLING (lips swollen), SWOLLEN TONGUE (Tongue swollen) and SWELLING FACE (Face swollen). On 07-May-2021, the patient experienced SKIN DISCOLOURATION (White spots). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (denied them their second dose due to their reaction to the first dose) and NECK MASS (lump on her neck). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 2 doses. At the time of the report, URTICARIA (Hives on her chest ) and NECK MASS (lump on her neck) was resolving and RASH (Rash), LIP SWELLING (lips swollen), SWOLLEN TONGUE (Tongue swollen), SWELLING FACE (Face swollen), SKIN DISCOLOURATION (White spots) and PRODUCT DOSE OMISSION ISSUE (denied them their second dose due to their reaction to the first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to US-MODERNATX, INC.-MOD-2021-138803 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-138803:Mother's case
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site hypoaesthesia, Pyrexia, Vaccination site pain
Clinical narrative: Numbness on the arm where he was injected; Soreness and pain on the arm where he was injected; feverish; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE HYPOAESTHESIA (Numbness on the arm where he was injected), VACCINATION SITE PAIN (Soreness and pain on the arm where he was injected) and PYREXIA (feverish) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026B21A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included ASCORBIC ACID, BIOTIN, TOCOPHERYL ACETATE (BIOTIN GUMMY) for an unknown indication.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, the patient experienced INJECTION SITE HYPOAESTHESIA (Numbness on the arm where he was injected), VACCINATION SITE PAIN (Soreness and pain on the arm where he was injected) and PYREXIA (feverish). The patient was treated with IBUPROFEN ongoing since an unknown date for Adverse event, at a dose of 800 milligram three times a day. At the time of the report, INJECTION SITE HYPOAESTHESIA (Numbness on the arm where he was injected), VACCINATION SITE PAIN (Soreness and pain on the arm where he was injected) and PYREXIA (feverish) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-139069 (Patient Link).
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Dehydration, Diarrhoea, Headache, Malaise, Nausea
Clinical narrative: feeling sick; dehydrated; Headache for 3 days; Nausea for 2 days; diarrhea; This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (Headache for 3 days), NAUSEA (Nausea for 2 days), DIARRHOEA (diarrhea), MALAISE (feeling sick) and DEHYDRATION (dehydrated) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048821A and 037821A) for COVID-19 vaccination.     The patient's past medical history included Surgery (surgery on left side due to beast cancer 4 yrs ago.).   On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-May-2021, the patient experienced DEHYDRATION (dehydrated). On an unknown date, the patient experienced HEADACHE (Headache for 3 days), NAUSEA (Nausea for 2 days), DIARRHOEA (diarrhea) and MALAISE (feeling sick). At the time of the report, HEADACHE (Headache for 3 days) and NAUSEA (Nausea for 2 days) had resolved and DIARRHOEA (diarrhea), MALAISE (feeling sick) and DEHYDRATION (dehydrated) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   concomitant medications were Oral medication for breast cancer provided by the reporter . Treatment information were not provided.   This case was linked to MOD-2021-138867 (Patient Link).
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: just pain in left arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (just pain in left arm) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036C21A) for COVID-19 vaccination.     Concomitant products included OCUVITE + LUTEIN, COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]) and VITAMIN C [ASCORBIC ACID] for an unknown indication.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-May-2021, the patient experienced PAIN IN EXTREMITY (just pain in left arm). The patient was treated with IBUPROFEN for Pain in arm, at an unspecified dose and frequency. On 17-May-2021, PAIN IN EXTREMITY (just pain in left arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       the treatment information was not provided.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Product dose omission issue
Clinical narrative: First dose 25feb2021 and never received second dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (First dose 25feb2021 and never received second dose) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (First dose 25feb2021 and never received second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (First dose 25feb2021 and never received second dose) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Apr-2021, COVID-19: positive (Positive) positive. On 15-Apr-2021, COVID-19: negative (Negative) negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. patient was unable to receive the second dose as scheduled on 25March2021 due to travel obligations. ..
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Vaginal haemorrhage
Clinical narrative: vaginal bleeding after receiving 1st dose of vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VAGINAL HAEMORRHAGE (vaginal bleeding after receiving 1st dose of vaccine) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination.     No Medical History was Reported.  Concomitant products included GABAPENTIN and PARACETAMOL (TYLENOL) for an unknown indication.    On 17-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-May-2021, the patient experienced VAGINAL HAEMORRHAGE (vaginal bleeding after receiving 1st dose of vaccine). At the time of the report, VAGINAL HAEMORRHAGE (vaginal bleeding after receiving 1st dose of vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication included acid reflux medication.  Patient states She had not had a menstrual cycle in 6 years.  No treatment medication were provided by the reporter.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Sore arm at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Apr-2021, the patient experienced VACCINATION SITE PAIN (Sore arm at the injection site). At the time of the report, VACCINATION SITE PAIN (Sore arm at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The concomitant medications were not reported. The treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-138343, US-MODERNATX, INC.-MOD-2021-138839, US-MODERNATX, INC.-MOD-2021-138889 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 17-Jun-2021: follow up received on 17-06-21 with gender; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-138343: US-MODERNATX, INC.-MOD-2021-138839: US-MODERNATX, INC.-MOD-2021-138889:
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site warmth, Vaccination site induration, Vaccination site pain, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Hot to the touch Injection Site; Hard to the touch Injection Site (After Second Dose); Itching Injection Site (After Second Dose); Swollen Injection Site (After Second Dose); Sore Injection Site (After Second Dose); This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE WARMTH (Hot to the touch Injection Site), VACCINATION SITE INDURATION (Hard to the touch Injection Site (After Second Dose)), VACCINATION SITE PRURITUS (Itching Injection Site (After Second Dose)), VACCINATION SITE SWELLING (Swollen Injection Site (After Second Dose)) and VACCINATION SITE PAIN (Sore Injection Site (After Second Dose)) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004C21A and 031B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-May-2021, the patient experienced INJECTION SITE WARMTH (Hot to the touch Injection Site), VACCINATION SITE INDURATION (Hard to the touch Injection Site (After Second Dose)), VACCINATION SITE PRURITUS (Itching Injection Site (After Second Dose)), VACCINATION SITE SWELLING (Swollen Injection Site (After Second Dose)) and VACCINATION SITE PAIN (Sore Injection Site (After Second Dose)). At the time of the report, INJECTION SITE WARMTH (Hot to the touch Injection Site), VACCINATION SITE INDURATION (Hard to the touch Injection Site (After Second Dose)), VACCINATION SITE PRURITUS (Itching Injection Site (After Second Dose)), VACCINATION SITE SWELLING (Swollen Injection Site (After Second Dose)) and VACCINATION SITE PAIN (Sore Injection Site (After Second Dose)) outcome was unknown.            Concomitant product use was not provided by the reporter. No treatment information was provided.   This case was linked to MOD-2021-138827 (Patient Link).
Age: 71.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Extra dose administered, Interchange of vaccine products
Clinical narrative: patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before; patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before; This spontaneous case was reported by a health care professional and describes the occurrence of EXTRA DOSE ADMINISTERED (patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before) and INTERCHANGE OF VACCINE PRODUCTS (patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 005C21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 12-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form. On 12-May-2021, the patient experienced EXTRA DOSE ADMINISTERED (patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before) and INTERCHANGE OF VACCINE PRODUCTS (patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before). At the time of the report, EXTRA DOSE ADMINISTERED (patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before) and INTERCHANGE OF VACCINE PRODUCTS (patient received a dose of the Moderna vaccine after receiving 2 doses of Pfizer before) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications were reported. No treatment medications were reported. The patient then stated that "her doctor told her that the Pfizer vaccine is not that good and that she should receive the Moderna vaccine instead.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Abdominal pain, Anxiety, Asthenia, COVID-19
Clinical narrative: has eczema; itches; fatigue; chills; slight pain at the injection site; muscle ache; headache; some sniffles; gets winded; anxiety; gastrointestinal (GI) issues; diarrhea; abdominal distress; abdominal cramping; hard to focus; slight confusion; forgetful; thinking Tuesday was Thursday; taking a shower takes a lot out of him; This spontaneous case was reported by a consumer and describes the occurrence of GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping) and DISTURBANCE IN ATTENTION (hard to focus) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in January 2021. Concurrent medical conditions included Gastrointestinal disorder.    On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, the patient experienced ASTHENIA (taking a shower takes a lot out of him). On 08-May-2021, the patient experienced GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping), DISTURBANCE IN ATTENTION (hard to focus), CONFUSIONAL STATE (slight confusion), MEMORY IMPAIRMENT (forgetful; thinking Tuesday was Thursday), RHINORRHOEA (some sniffles), DYSPNOEA (gets winded), ANXIETY (anxiety), FATIGUE (fatigue), CHILLS (chills), INJECTION SITE PAIN (slight pain at the injection site), MYALGIA (muscle ache) and HEADACHE (headache). On an unknown date, the patient experienced ECZEMA (has eczema) and PRURITUS (itches). At the time of the report, GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping), DISTURBANCE IN ATTENTION (hard to focus), CONFUSIONAL STATE (slight confusion), MEMORY IMPAIRMENT (forgetful; thinking Tuesday was Thursday), ECZEMA (has eczema), RHINORRHOEA (some sniffles), DYSPNOEA (gets winded), ANXIETY (anxiety), ASTHENIA (taking a shower takes a lot out of him), PRURITUS (itches), FATIGUE (fatigue), CHILLS (chills), INJECTION SITE PAIN (slight pain at the injection site), MYALGIA (muscle ache) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, COVID-19: negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Patient went to the hospital ER, tested negative for COVID-19 and had normal bloodwork. Treatment information not provided.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Confusional state, Diarrhoea, Disturbance in attention, Dyspnoea
Clinical narrative: has eczema; itches; fatigue; chills; slight pain at the injection site; muscle ache; headache; some sniffles; gets winded; anxiety; gastrointestinal (GI) issues; diarrhea; abdominal distress; abdominal cramping; hard to focus; slight confusion; forgetful; thinking Tuesday was Thursday; taking a shower takes a lot out of him; This spontaneous case was reported by a consumer and describes the occurrence of GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping) and DISTURBANCE IN ATTENTION (hard to focus) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in January 2021. Concurrent medical conditions included Gastrointestinal disorder.    On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, the patient experienced ASTHENIA (taking a shower takes a lot out of him). On 08-May-2021, the patient experienced GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping), DISTURBANCE IN ATTENTION (hard to focus), CONFUSIONAL STATE (slight confusion), MEMORY IMPAIRMENT (forgetful; thinking Tuesday was Thursday), RHINORRHOEA (some sniffles), DYSPNOEA (gets winded), ANXIETY (anxiety), FATIGUE (fatigue), CHILLS (chills), INJECTION SITE PAIN (slight pain at the injection site), MYALGIA (muscle ache) and HEADACHE (headache). On an unknown date, the patient experienced ECZEMA (has eczema) and PRURITUS (itches). At the time of the report, GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping), DISTURBANCE IN ATTENTION (hard to focus), CONFUSIONAL STATE (slight confusion), MEMORY IMPAIRMENT (forgetful; thinking Tuesday was Thursday), ECZEMA (has eczema), RHINORRHOEA (some sniffles), DYSPNOEA (gets winded), ANXIETY (anxiety), ASTHENIA (taking a shower takes a lot out of him), PRURITUS (itches), FATIGUE (fatigue), CHILLS (chills), INJECTION SITE PAIN (slight pain at the injection site), MYALGIA (muscle ache) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, COVID-19: negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Patient went to the hospital ER, tested negative for COVID-19 and had normal bloodwork. Treatment information not provided.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Eczema, Fatigue, Gastrointestinal disorder, Headache, Injection site pain
Clinical narrative: has eczema; itches; fatigue; chills; slight pain at the injection site; muscle ache; headache; some sniffles; gets winded; anxiety; gastrointestinal (GI) issues; diarrhea; abdominal distress; abdominal cramping; hard to focus; slight confusion; forgetful; thinking Tuesday was Thursday; taking a shower takes a lot out of him; This spontaneous case was reported by a consumer and describes the occurrence of GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping) and DISTURBANCE IN ATTENTION (hard to focus) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in January 2021. Concurrent medical conditions included Gastrointestinal disorder.    On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Mar-2021, the patient experienced ASTHENIA (taking a shower takes a lot out of him). On 08-May-2021, the patient experienced GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping), DISTURBANCE IN ATTENTION (hard to focus), CONFUSIONAL STATE (slight confusion), MEMORY IMPAIRMENT (forgetful; thinking Tuesday was Thursday), RHINORRHOEA (some sniffles), DYSPNOEA (gets winded), ANXIETY (anxiety), FATIGUE (fatigue), CHILLS (chills), INJECTION SITE PAIN (slight pain at the injection site), MYALGIA (muscle ache) and HEADACHE (headache). On an unknown date, the patient experienced ECZEMA (has eczema) and PRURITUS (itches). At the time of the report, GASTROINTESTINAL DISORDER (gastrointestinal (GI) issues), DIARRHOEA (diarrhea), ABDOMINAL DISCOMFORT (abdominal distress), ABDOMINAL PAIN (abdominal cramping), DISTURBANCE IN ATTENTION (hard to focus), CONFUSIONAL STATE (slight confusion), MEMORY IMPAIRMENT (forgetful; thinking Tuesday was Thursday), ECZEMA (has eczema), RHINORRHOEA (some sniffles), DYSPNOEA (gets winded), ANXIETY (anxiety), ASTHENIA (taking a shower takes a lot out of him), PRURITUS (itches), FATIGUE (fatigue), CHILLS (chills), INJECTION SITE PAIN (slight pain at the injection site), MYALGIA (muscle ache) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, COVID-19: negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Patient went to the hospital ER, tested negative for COVID-19 and had normal bloodwork. Treatment information not provided.